Summary
For Year 2026-27, Balaxi Pharmaceuticals reports the following shareholding: Total Promoters at 65.99%, Mutual Fund at 0%, Insurance at 0%, Foreign Institutional Investors at 0%, Domestic Institutional Investors at 2.56%, and Retail at 31.45%. This breakdown provides a quick snapshot of ownership distribution for Balaxi Pharmaceuticals in 2026-27.
Balaxi Pharmaceuticals FAQs
As of 05-2026, the promoter shareholding in Balaxi Pharmaceuticals stands at 65.99% of the company's total shares. Promoter shareholding represents the ownership stake held by the company's founding members, management, or controlling entities, having a significant influence on the company's strategic direction and operations.
The FII and DII shareholding of Balaxi Pharmaceuticals is 0% and 2.56% respectively.
The retail shareholding of the Balaxi Pharmaceuticals is 31.45%.
Changes in shareholding patterns of Balaxi Pharmaceuticals can result from stock market transactions, issuance of new shares, buybacks, mergers, acquisitions, or changes in promoter holdings.
Shareholding patterns of Balaxi Pharmaceuticals are updated quarterly as mandated by regulatory authorities and may also be disclosed during significant corporate events.
The latest shareholding pattern is available on stock exchanges (e.g., NSE, BSE) and the company's official website under investor relations.
Balaxi Pharmaceuticals Associated Pages
